Injury markers predict time to dementia in subjects with MCI and amyloid pathology.

Objectives: Alzheimer disease (AD) can now be diagnosed in subjects with mild cognitive impairment (MCI) using biomarkers. However, little is known about the rate of decline in those subjects. In this cohort study, we aimed to assess the conversion rate to dementia and identify prognostic markers in...

Descripción completa

Detalles Bibliográficos
Publicado en:Neurology Vol. 79; no. 17; pp. 1809 - 1817
Autores principales: van Rossum IA, Vos SJ, Burns L, Knol DL, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, L'italien G, van der Flier WM, Teunissen CE, Blennow K, Barkhof F, Rueckert D, Wolz R, Verhey F, Visser PJ, van Rossum, Ineke A
Formato: research Journal Article
Publicado: Lippincott Williams & Wilkins 10/23/2012
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=108083423&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 108083423
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00283878
        NRO
      jtl: Neurology
      issn: 00283878
      maglogo: N
    pubinfo:
      dt: 10/23/2012
      vid: 79
      iid: 17
      pid: 433
      pub: Lippincott Williams & Wilkins
      place: Baltimore, Maryland
    artinfo:
      ui:
        108083423
        108083423
        NLM23019259
        2011791484
        10.1212/WNL.0b013e3182704056
        NLM23019259
        PMC3475623
        108083423
      ppf: 1809
      ppct: 8
      formats:
      tig:
        atl: Injury markers predict time to dementia in subjects with MCI and amyloid pathology.
      aug:
        au:
          van Rossum IA
          Vos SJ
          Burns L
          Knol DL
          Scheltens P
          Soininen H
          Wahlund LO
          Hampel H
          Tsolaki M
          Minthon L
          L'italien G
          van der Flier WM
          Teunissen CE
          Blennow K
          Barkhof F
          Rueckert D
          Wolz R
          Verhey F
          Visser PJ
          van Rossum, Ineke A
        affil: Department of Neurology, Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands
      sug:
        subj:
          Alzheimer's Disease Pathology
          Peptides Metabolism
          Apolipoproteins
          Hippocampus Pathology
          Cognition Disorders
          Aged
          Alzheimer's Disease Cerebrospinal Fluid
          Alzheimer's Disease
          Biological Markers Cerebrospinal Fluid
          Prospective Studies
          Disease Progression
          Female
          Human
          Male
          Cognition Disorders Cerebrospinal Fluid
          Cognition Disorders Diagnosis
          Multicenter Studies
          Neuropsychological Tests
          Predictive Value of Tests
          Psychological Tests
          Time Factors
          Nerve Tissue Proteins Cerebrospinal Fluid
          Aged: 65+ years
          Female
          Male
      ab: Objectives: Alzheimer disease (AD) can now be diagnosed in subjects with mild cognitive impairment (MCI) using biomarkers. However, little is known about the rate of decline in those subjects. In this cohort study, we aimed to assess the conversion rate to dementia and identify prognostic markers in subjects with MCI and evidence of amyloid pathology.Methods: We pooled subjects from the VU University Medical Center Alzheimer Center and the Development of Screening Guidelines and Criteria for Predementia Alzheimer's Disease (DESCRIPA) study. We included subjects with MCI, an abnormal level of β-amyloid(1-42) (Aβ(1-42)) in the CSF, and at least one diagnostic follow-up visit. We assessed the effect of APOE genotype, CSF total tau (t-tau) and tau phosphorylated at threonine 181 (p-tau) and hippocampal volume on time to AD-type dementia using Cox proportional hazards models and on decline on the Mini-Mental State Examination (MMSE) using linear mixed models.Results: We included 110 subjects with MCI with abnormal CSF Aβ(1-42) and a mean MMSE score of 26.3 ± 2.8. During a mean follow-up of 2.2 ± 1.0 (range 0.4-5.0) years, 63 subjects (57%) progressed to AD-type dementia. Abnormal CSF t-tau (hazard ratio [HR] 2.3, 95% confidence interval [CI] 1.1-4.6, p = 0.03) and CSF p-tau (HR 3.5, 95% CI 1.3-9.2, p = 0.01) concentration and hippocampal atrophy (HR 2.5, 95% CI 1.1-5.6, p = 0.02) predicted time to dementia. For subjects with both abnormal t-tau concentration and hippocampal atrophy, HR was 7.3 (95% CI 1.0-55.9, p = 0.06). Furthermore, abnormal CSF t-tau and p-tau concentrations and hippocampal atrophy predicted decline in MMSE score.Conclusions: In subjects with MCI and evidence of amyloid pathology, the injury markers CSF t-tau and p-tau and hippocampal atrophy can predict further cognitive decline.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N